Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,025 | 115 | 910 |
| Samples | 195 | 24 | 171 |
| Peptides | 213 | 27 | 187 |
Function
TTC26 · Intraflagellar transport protein 56
Component of the intraflagellar transport (IFT) complex B required for transport of proteins in the motile cilium. Required for transport of specific ciliary cargo proteins related to motility, while it is neither required for IFT complex B assembly or motion nor for cilium assembly. Required for efficient coupling between the accumulation of GLI2 and GLI3 at the ciliary tips and their dissociation from the negative regulator SUFU. Plays a key role in maintaining the integrity of the IFT complex B and the proper ciliary localization of the IFT complex B components. Not required for IFT complex A ciliary localization or function. Essential for maintaining proper microtubule organization within the ciliary axoneme
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 172 amino-acid changes on canonical ENST00000464848 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TTC26 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TTC26 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 15/612 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 2/210 1% | 27/1899 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Colorectal Carcinoma | 5/143 4% | 24/3239 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 8/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Other Solid Cancers | 1/94 1% | 11/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Gastric Carcinoma | 0/74 0% | 12/1809 1% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 9/2210 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Kidney Carcinoma | 0/85 0% | 7/1862 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Breast Carcinoma | 0/144 0% | 5/3264 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 1/2534 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 1/2550 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 1/2640 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 1/1592 0% |
Mutation Distribution
Where TTC26 is mutated · all tissues, split by cell line vs tissue
How many mutations in TTC26 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,025 mutations in TTC26
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|